Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality

Engineered T cells work as living therapeutics, but are prone to hyperreactivity and exhaustion. Here the authors improve CAR T cell antitumor responses by simultaneously targeting a CAR to TCR locus and IL-12 to PD1 locus, placing the transgenes under a naturally regulated transcriptional network w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mohit Sachdeva, Brian W. Busser, Sonal Temburni, Billal Jahangiri, Anne-Sophie Gautron, Alan Maréchal, Alexandre Juillerat, Alan Williams, Stéphane Depil, Philippe Duchateau, Laurent Poirot, Julien Valton
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Q
Acceso en línea:https://doaj.org/article/981675c72a9b4f029d140df08e0be5fe
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Engineered T cells work as living therapeutics, but are prone to hyperreactivity and exhaustion. Here the authors improve CAR T cell antitumor responses by simultaneously targeting a CAR to TCR locus and IL-12 to PD1 locus, placing the transgenes under a naturally regulated transcriptional network while disrupting unwanted signals.